Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ivarmacitinib effectively regrows hair in severe alopecia areata.

This case report documents acquired progressive kinking of the hair in a prepubertal boy but does not provide new clinical results.

This report discusses the accurate diagnosis of atrichia with papular lesions, emphasizing its distinction from alopecia universalis to prevent unnecessary steroid treatment, and presents a case matching APL diagnostic criteria.

In this study, researchers focused on the "bulge region" of hair follicles, identifying Janus kinases as key players in hair growth signaling, which could inform new therapies for hair restoration.

This review discusses primary neutrophilic cicatricial alopecias, their clinical and histological characteristics, and the importance of early therapeutic intervention to prevent scarring alopecia, reporting no new clinical results.

This source did not report new findings but provided a comprehensive overview of alopecia areata in children, emphasizing progress in understanding this condition and highlighting the need for further research to improve treatment options for young patients.

This study observed a high prevalence of severe markers among pediatric alopecia areata patients, identifying AA subtotalis as more frequent, with nail changes and various hair markers suggesting progression to severe forms.

This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.

This case report describes the treatment of a 12-year-old female with Alopecia Areata using oral azathioprine.

This report presents a case of alopecia areata manifesting in a linear pattern, deviating from the typical presentation of sharply demarcated round patches.

This study found that most dermatologists in the Middle East manage mild to severe alopecia areata primarily with potent topical corticosteroids and identified long-term disease control and improved efficacy as key unmet needs.

This study suggests the existence of a new subtype of alopecia, called 'acute diffuse and total alopecia of the female scalp (ADTAFS)', characterized by acute, diffuse hair loss primarily in women and a rapid recovery.

This case report describes a 25-year-old woman with alopecia areata and nail spooning, which regressed almost completely after treatment with oral corticosteroids.

This study reports a strong association between the MICA locus, specifically the MICA∗3-DR∗6-DQ6 haplotype, and Alopecia Areata in families.

This article proposes a hypothesis for alopecia areata hair loss patterns and provides epidemiological evidence supporting distinct hair loss characteristics between general cases and those with androgenetic alopecia; it presents no new clinical results.

This study observed two distinct groups of alopecia areata lesions based on PD-1 expression in T cells from biopsied skin samples, suggesting potential differences in subtypes or stages of the disease that warrant further investigation.

This study found that abrocitinib showed promising efficacy and safety in adolescents with moderate-to-severe alopecia areata, with significant hair regrowth observed over 10 months of treatment.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This study found that ischemia-modified albumin (IMA) may be a promising biomarker of oxidative stress in patients with alopecia areata, offering better potential compared to other oxidative stress markers.

This study explores how Astragaloside A from traditional Chinese medicine may combat lung adenocarcinoma by regulating key signaling molecules like STAT3 and AKT, using techniques such as network pharmacology and molecular docking to understand its mechanisms in cellular models.

Farudodstat may effectively treat alopecia areata without harmful side effects.

This study observed that patients with acute alopecia areata treated with Janus kinase inhibitors achieved a higher rate of complete hair regrowth by week 24 compared to those with non-acute disease, highlighting the benefits of early intervention.

This article reviews factors influencing hair growth and treatment options for androgenetic alopecia, but it reports no new clinical results on their effectiveness.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This study highlights the use of dermatoscopy as a valuable tool for diagnosing and monitoring alopecia areata, noting that specific hair shaft alterations such as exclamation-mark hairs and black dots are indicators of active disease, while vellus hairs signal early regrowth.